Freedom of Information Request ID
7272
Date of response
April 2022
Q1. Does your trust treat myelofibrosis? If not, which other trust do you refer these patients to?
Q2. A) Please provide the total number of patients treated in the last 6 months (or the latest 6 months data you have available) for myelofibrosis (ICD10 code D47.4).
- b) How many of these patients were above age 65?
Q3. How many myelofibrosis patients were treated in the past 6 months with Ruxolitinib?
Q4. a) How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years?
- b) Of these patients, how many were treated in the past 6 months (or the latest 6 months data you have available) with:
- Hydroxyurea
- Fedratinib
- Received No Treatment
Medway NHS Foundation Trust regret that we are unable to answer these questions as this data is not collated specifically for patients with myelofibrosis. The Trust’s Pharmacy department can confirm the number of patients who have been supplied the drugs, however, Pharmacy records do not show the indication for the treatment or what the drug was prescribed for, This is for the Reporting Period: 1/10/21 to 31/03/22. Please note If the drug is not listed, it is because it has not been listed.
HYDROXYCARBAMIDE
Total number of patients: 81
HYDROXYCARBAMIDE (SIKLOS)
Total number of patients: 6
HYDROXYCARBAMIDE (XROMI)
Total number of patients: <5
RUXOLITINIB
Total number of patients: <5
Q5. Does your trust participate in any clinical trials for the treatment of myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part.
No, we have no trials in Medway NHS Foundation Trust for this diagnosis.
FOI Requests
The Freedom of Information Act 2000 provides people with a right of access to a wide range of information held by public authorities, including the NHS.
FOI Disclosure Log
A collection of the most common FOI requests we have received and responded to.
